Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Patients with difficult-to-treat depression do not exhibit an increased frequency of CYP2D6 allele duplication.

Pharmacopsychiatry - 1 Jun 2013

Háber A, Rideg O, Osváth P, Fekete S, Szücs F, Fittler A, Kovács G L, Miseta A, Botz L

Abstract excerpt

The insufficient response of patients to antidepressant medications may result from several factors, including altered drug metabolism. CYP2D6 genotyping may help assess the possible factors that contribute to difficult-to-treat depression. The aim of our study was to determine the frequency of C...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Alleles
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Depressive Disorder, Major

Share to Gene Duplication

Share to Gene Frequency

Share to Hungary

Source

Identifiers

PMID: 23737191
DOI: 10.1055/s-0033-1343397

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23737191-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Patients with difficult-to-treat depression do not exhibit an increased frequency of CYP2D6 allele duplication.PMID 23737191Read ↗

Aberrant CYP2D6 metabolizer phenotypes do not show increased frequency in patients undergoing ECT after antidepressant therapy.Semantic proximity Read ↗

Risk Phenotypes, Comorbidities, Pharmacotherapy, and Electroconvulsive Therapy (ECT) in a Cohort with Difficult-to-Treat Depression in Comparison to an Unmedicated Control Group.Semantic proximity Read ↗

Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study.Semantic proximity Read ↗

Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype.Semantic proximity Read ↗

The Role of Genetics in the Development and Pharmacotherapy of Depression and Its Impact on Drug DiscoverySemantic proximity Read ↗

Identification of CYP2D6 allelic mutations in a sub-set of Karachi populationSemantic proximity Read ↗

Identification of CYP2D6 allelic mutations in a sub-set of Karachi populationSemantic proximity Read ↗

Integrating Genetic Variants and Expression Profiles of Pharmacogenes to Investigate Resistance to Antidepressant Treatment.Semantic proximity Read ↗

Integrating Genetic Variants and Expression Profiles of Pharmacogenes in Treatment- Resistant DepressionSemantic proximity Read ↗

[Clinical interest of CYP2D6 genotyping to treat depression in practice].Semantic proximity Read ↗

Rates of Divergent Pharmacogenes in a Psychiatric Cohort of Inpatients with Depression—Arguments for Preemptive TestingSemantic proximity Read ↗

CYP2D6 Genotyping and Inhibition as Predictors of Adverse Drug Reactions in Depressive Disorders.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.